NASDAQ · Biotechnology

Grace Therapeutics, Inc. (GRCE) Stock

$2.08 +1.96% NASDAQ: GRCE Healthcare

Valuation

MetricValue
Price$2.08
Market Cap$33.85M
P/E Ratio-1.64
P/B Ratio0.74
P/S Ratio0.00
EPS (TTM)$-0.95
52-Week High$5.18
52-Week Low$1.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.78%
ROA-42.84%
ROCE-52.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.50

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-71.0M$-17.0M$-24.0M$-11.0M
Net Profit$-12.0M$-57.0M$-17.0M$-14.0M$-8.0M
EPS$-2.02$-7.72$-1.83$-1.13$-0.47
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$129.0M$79.0M$73.0M$72.0M$67.0M
Total Liabilities$20.0M$11.0M$12.0M$5.0M$3.0M
Cash$30.0M$28.0M$23.0M$22.0M$17.0M
Borrowings$0$0$0$0$0

Latest News

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update GlobeNewswire · Jun 18, 2026 Sector Update: Health Care Stocks Edge Lower Late Afternoon MT Newswires · Apr 23, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-17.0M$-16.0M$-12.0M$-15.0M$-9.0M
Investing Cash Flow$-4.0M$13.0M$0$0$0
Financing Cash Flow$0$0$0$-1.0M$0
Net Cash Flow$-21.0M$-2.0M$-5.0M$-1.0M$-5.0M
Free Cash Flow$-17.0M$-16.0M$-12.0M$-15.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.77
FCF Yield-30.73%
Quick Ratio11.47
Interest Coverage—
Return 1Y-23.35%
Return 3Y-2.20%
Return 5Y-89.81%

Ownership

Insiders Held25.73%
Institutions Held26.46%
Institutions Float Held35.62%
Institutional HolderSharesReport Date
Cerity Partners LLC849,0552026-03-31
Eversept Partners, LP756,6002026-03-31
Nantahala Capital Management, LLC728,2032026-03-31
Bank of America Corporation494,7232026-03-31
Vanguard Capital Management LLC401,6562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVCABVC BioPharma, Inc. $1.00 +2.04% -3.42 $26.00M 0.00%
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.10 +1.85% 3.25 $34.51M 0.00%
CALCCalciMedica, Inc. $1.27 -2.31% -0.21 $4.00M 0.00%
LTRNLantern Pharma Inc. $0.81 -2.08% -0.51 $10.37M 0.00%
LVTXLAVA Therapeutics N.V. $1.74 -3.87% -2.42 $45.77M 0.00%

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is led by CEO Prashant Kohli, employs 4 people, headquartered in US, publicly traded since 2012.

Grace Therapeutics, Inc. (GRCE) stock trades at $2.08 with a market capitalization of $33.85M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.64, reflecting a net loss over the last twelve months, price-to-book of 0.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.79 and $5.18, and currently trades 59.8% below its 52-week high.

On profitability, Grace Therapeutics, Inc. generates a return on equity (ROE) of -35.78% (negative, reflecting a net loss), return on capital employed of -52.61%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.